About Forbion Capital Partners
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Investment Details
Investment Range
Not specified
Investment Stage
Various stages
Industry Focus
Climate, Edtech, Education (+5 more)
Investor Type
Private Equity Firm, Venture Capital
Investment Focus
Focus Areas
Investment Stages